Perceived  ||| S:0 E:10 ||| VBN
versus  ||| S:10 E:17 ||| IN
objective  ||| S:17 E:27 ||| JJ
breast  ||| S:27 E:34 ||| NN
cancer  ||| S:34 E:41 ||| NN
risk  ||| S:41 E:46 ||| NN
in  ||| S:46 E:49 ||| IN
diverse  ||| S:49 E:57 ||| JJ
women  ||| S:57 E:63 ||| NNS
Prior  ||| S:63 E:69 ||| RB
research  ||| S:69 E:78 ||| NN
suggests  ||| S:78 E:87 ||| VBZ
that  ||| S:87 E:92 ||| IN
women  ||| S:92 E:98 ||| NNS
do  ||| S:98 E:101 ||| VBP
not  ||| S:101 E:105 ||| RB
accurately  ||| S:105 E:116 ||| RB
estimate  ||| S:116 E:125 ||| VB
their  ||| S:125 E:131 ||| PRP$
risk  ||| S:131 E:136 ||| NN
for  ||| S:136 E:140 ||| IN
breast  ||| S:140 E:147 ||| JJ
cancer ||| S:147 E:153 ||| NN
.  ||| S:153 E:155 ||| .
Estimating  ||| S:155 E:166 ||| NNP
and  ||| S:166 E:170 ||| CC
informing  ||| S:170 E:180 ||| VBG
women  ||| S:180 E:186 ||| NNS
of  ||| S:186 E:189 ||| IN
their  ||| S:189 E:195 ||| PRP$
risk  ||| S:195 E:200 ||| NN
is  ||| S:200 E:203 ||| VBZ
essential  ||| S:203 E:213 ||| JJ
for  ||| S:213 E:217 ||| IN
tailoring  ||| S:217 E:227 ||| VBG
appropriate  ||| S:227 E:239 ||| JJ
screening  ||| S:239 E:249 ||| NN
and  ||| S:249 E:253 ||| CC
risk  ||| S:253 E:258 ||| NN
reduction  ||| S:258 E:268 ||| NN
strategies ||| S:268 E:278 ||| NNS
.  ||| S:278 E:280 ||| .
Data  ||| S:280 E:285 ||| NNP
were  ||| S:285 E:290 ||| VBD
collected  ||| S:290 E:300 ||| VBN
for  ||| S:300 E:304 ||| IN
BreastCARE ||| S:304 E:314 ||| NNP
,  ||| S:314 E:316 ||| ,
a  ||| S:316 E:318 ||| DT
randomized  ||| S:318 E:329 ||| JJ
controlled  ||| S:329 E:340 ||| JJ
trial  ||| S:340 E:346 ||| NN
designed  ||| S:346 E:355 ||| VBN
to  ||| S:355 E:358 ||| TO
evaluate  ||| S:358 E:367 ||| VB
a  ||| S:367 E:369 ||| DT
PC-tablet  ||| S:369 E:379 ||| JJ
based  ||| S:379 E:385 ||| VBN
intervention  ||| S:385 E:398 ||| NN
providing  ||| S:398 E:408 ||| VBG
multiethnic  ||| S:408 E:420 ||| JJ
women  ||| S:420 E:426 ||| NNS
and  ||| S:426 E:430 ||| CC
their  ||| S:430 E:436 ||| PRP$
primary  ||| S:436 E:444 ||| JJ
care  ||| S:444 E:449 ||| NN
physicians  ||| S:449 E:460 ||| NNS
with  ||| S:460 E:465 ||| IN
tailored  ||| S:465 E:474 ||| JJ
information  ||| S:474 E:486 ||| NN
about  ||| S:486 E:492 ||| IN
breast  ||| S:492 E:499 ||| JJ
cancer  ||| S:499 E:506 ||| NN
risk ||| S:506 E:510 ||| NN
.  ||| S:510 E:512 ||| .
We  ||| S:512 E:515 ||| PRP
included  ||| S:515 E:524 ||| VBD
women  ||| S:524 E:530 ||| NNS
ages  ||| S:530 E:535 ||| NNS
40-74  ||| S:535 E:541 ||| VBP
visiting  ||| S:541 E:550 ||| VBG
general  ||| S:550 E:558 ||| JJ
internal  ||| S:558 E:567 ||| JJ
medicine  ||| S:567 E:576 ||| NN
primary  ||| S:576 E:584 ||| JJ
care  ||| S:584 E:589 ||| NN
clinics  ||| S:589 E:597 ||| NNS
at  ||| S:597 E:600 ||| IN
one  ||| S:600 E:604 ||| CD
academic  ||| S:604 E:613 ||| JJ
practice  ||| S:613 E:622 ||| NN
and  ||| S:622 E:626 ||| CC
one  ||| S:626 E:630 ||| CD
safety  ||| S:630 E:637 ||| NN
net  ||| S:637 E:641 ||| JJ
practice  ||| S:641 E:650 ||| NN
who  ||| S:650 E:654 ||| WP
spoke  ||| S:654 E:660 ||| VBD
English ||| S:660 E:667 ||| NNP
,  ||| S:667 E:669 ||| ,
Spanish ||| S:669 E:676 ||| NNP
,  ||| S:676 E:678 ||| ,
or  ||| S:678 E:681 ||| CC
Cantonese ||| S:681 E:690 ||| NNP
,  ||| S:690 E:692 ||| ,
and  ||| S:692 E:696 ||| CC
had  ||| S:696 E:700 ||| VBD
no  ||| S:700 E:703 ||| DT
personal  ||| S:703 E:712 ||| JJ
history  ||| S:712 E:720 ||| NN
of  ||| S:720 E:723 ||| IN
breast  ||| S:723 E:730 ||| JJ
cancer ||| S:730 E:736 ||| NN
.  ||| S:736 E:738 ||| .
We  ||| S:738 E:741 ||| PRP
collected  ||| S:741 E:751 ||| VBD
baseline  ||| S:751 E:760 ||| JJ
information  ||| S:760 E:772 ||| NN
regarding  ||| S:772 E:782 ||| VBG
risk  ||| S:782 E:787 ||| NN
perception  ||| S:787 E:798 ||| NN
and  ||| S:798 E:802 ||| CC
concern ||| S:802 E:809 ||| NN
.  ||| S:809 E:811 ||| .
Women  ||| S:811 E:817 ||| NNS
were  ||| S:817 E:822 ||| VBD
categorized  ||| S:822 E:834 ||| VBN
as  ||| S:834 E:837 ||| IN
high  ||| S:837 E:842 ||| JJ
risk  ||| S:842 E:847 ||| NN
( ||| S:847 E:848 ||| -LRB-
vs.  ||| S:848 E:852 ||| FW
average  ||| S:852 E:860 ||| JJ
risk ||| S:860 E:864 ||| NN
)  ||| S:864 E:866 ||| -RRB-
if  ||| S:866 E:869 ||| IN
their  ||| S:869 E:875 ||| PRP$
family  ||| S:875 E:882 ||| NN
history  ||| S:882 E:890 ||| NN
met  ||| S:890 E:894 ||| VBD
criteria  ||| S:894 E:903 ||| NNS
for  ||| S:903 E:907 ||| IN
referral  ||| S:907 E:916 ||| NN
to  ||| S:916 E:919 ||| TO
genetic  ||| S:919 E:927 ||| JJ
counseling  ||| S:927 E:938 ||| NN
or  ||| S:938 E:941 ||| CC
if  ||| S:941 E:944 ||| IN
they  ||| S:944 E:949 ||| PRP
were  ||| S:949 E:954 ||| VBD
in  ||| S:954 E:957 ||| IN
the  ||| S:957 E:961 ||| DT
top  ||| S:961 E:965 ||| JJ
5 ||| S:965 E:966 ||| CD
%  ||| S:966 E:968 ||| NN
of  ||| S:968 E:971 ||| IN
risk  ||| S:971 E:976 ||| NN
for  ||| S:976 E:980 ||| IN
their  ||| S:980 E:986 ||| PRP$
age  ||| S:986 E:990 ||| NN
based  ||| S:990 E:996 ||| VBN
on  ||| S:996 E:999 ||| IN
the  ||| S:999 E:1003 ||| DT
Gail  ||| S:1003 E:1008 ||| NNP
or  ||| S:1008 E:1011 ||| CC
Breast  ||| S:1011 E:1018 ||| NNP
Cancer  ||| S:1018 E:1025 ||| NNP
Surveillance  ||| S:1025 E:1038 ||| NNP
Consortium  ||| S:1038 E:1049 ||| NNP
Model  ||| S:1049 E:1055 ||| NNP
( ||| S:1055 E:1056 ||| -LRB-
BCSC ||| S:1056 E:1060 ||| NNP
)  ||| S:1060 E:1062 ||| -RRB-
breast  ||| S:1062 E:1069 ||| NN
cancer  ||| S:1069 E:1076 ||| NN
risk  ||| S:1076 E:1081 ||| NN
model ||| S:1081 E:1086 ||| NN
.  ||| S:1086 E:1088 ||| .
Of  ||| S:1088 E:1091 ||| IN
1,261  ||| S:1091 E:1097 ||| CD
participants ||| S:1097 E:1109 ||| NNS
,  ||| S:1109 E:1111 ||| ,
25 ||| S:1111 E:1113 ||| CD
%  ||| S:1113 E:1115 ||| NN
( ||| S:1115 E:1116 ||| -LRB-
N=314 ||| S:1116 E:1121 ||| NNP
)  ||| S:1121 E:1123 ||| -RRB-
were  ||| S:1123 E:1128 ||| VBD
classified  ||| S:1128 E:1139 ||| VBN
as  ||| S:1139 E:1142 ||| IN
high  ||| S:1142 E:1147 ||| JJ
risk ||| S:1147 E:1151 ||| NN
.  ||| S:1151 E:1153 ||| .
More  ||| S:1153 E:1158 ||| RBR
average  ||| S:1158 E:1166 ||| JJ
risk  ||| S:1166 E:1171 ||| NN
than  ||| S:1171 E:1176 ||| IN
high  ||| S:1176 E:1181 ||| JJ
risk  ||| S:1181 E:1186 ||| NN
women  ||| S:1186 E:1192 ||| NNS
had  ||| S:1192 E:1196 ||| VBD
correct  ||| S:1196 E:1204 ||| JJ
risk  ||| S:1204 E:1209 ||| NN
perception  ||| S:1209 E:1220 ||| NN
( ||| S:1220 E:1221 ||| -LRB-
72 ||| S:1221 E:1223 ||| CD
%  ||| S:1223 E:1225 ||| NN
vs.  ||| S:1225 E:1229 ||| IN
18 ||| S:1229 E:1231 ||| CD
% ||| S:1231 E:1232 ||| NN
) ||| S:1232 E:1233 ||| -RRB-
;  ||| S:1233 E:1235 ||| :
25 ||| S:1235 E:1237 ||| CD
%  ||| S:1237 E:1239 ||| NN
of  ||| S:1239 E:1242 ||| IN
both  ||| S:1242 E:1247 ||| DT
average  ||| S:1247 E:1255 ||| NN
and  ||| S:1255 E:1259 ||| CC
high  ||| S:1259 E:1264 ||| JJ
risk  ||| S:1264 E:1269 ||| NN
women  ||| S:1269 E:1275 ||| NNS
reported  ||| S:1275 E:1284 ||| VBD
being  ||| S:1284 E:1290 ||| VBG
very  ||| S:1290 E:1295 ||| RB
concerned  ||| S:1295 E:1305 ||| VBN
about  ||| S:1305 E:1311 ||| IN
breast  ||| S:1311 E:1318 ||| JJ
cancer ||| S:1318 E:1324 ||| NN
.  ||| S:1324 E:1326 ||| .
Average  ||| S:1326 E:1334 ||| JJ
risk  ||| S:1334 E:1339 ||| NN
women  ||| S:1339 E:1345 ||| NNS
with  ||| S:1345 E:1350 ||| IN
correct  ||| S:1350 E:1358 ||| JJ
risk  ||| S:1358 E:1363 ||| NN
perception  ||| S:1363 E:1374 ||| NN
were  ||| S:1374 E:1379 ||| VBD
less  ||| S:1379 E:1384 ||| RBR
likely  ||| S:1384 E:1391 ||| JJ
to  ||| S:1391 E:1394 ||| TO
be  ||| S:1394 E:1397 ||| VB
concerned  ||| S:1397 E:1407 ||| VBN
about  ||| S:1407 E:1413 ||| IN
breast  ||| S:1413 E:1420 ||| JJ
cancer  ||| S:1420 E:1427 ||| NN
( ||| S:1427 E:1428 ||| -LRB-
odds  ||| S:1428 E:1433 ||| JJ
ratio  ||| S:1433 E:1439 ||| NN
[ ||| S:1439 E:1440 ||| -LRB-
OR ||| S:1440 E:1442 ||| NNP
] ||| S:1442 E:1443 ||| -RRB-
=0.3 ||| S:1443 E:1447 ||| SYM
;  ||| S:1447 E:1449 ||| :
95 ||| S:1449 E:1451 ||| CD
%  ||| S:1451 E:1453 ||| NN
confidence  ||| S:1453 E:1464 ||| NN
interval  ||| S:1464 E:1473 ||| NNS
[ ||| S:1473 E:1474 ||| -LRB-
CI ||| S:1474 E:1476 ||| NNP
] ||| S:1476 E:1477 ||| -RRB-
=0.2-0.4 ||| S:1477 E:1485 ||| CD
)  ||| S:1485 E:1487 ||| -RRB-
while  ||| S:1487 E:1493 ||| IN
high  ||| S:1493 E:1498 ||| JJ
risk  ||| S:1498 E:1503 ||| NN
women  ||| S:1503 E:1509 ||| NNS
with  ||| S:1509 E:1514 ||| IN
correct  ||| S:1514 E:1522 ||| JJ
risk  ||| S:1522 E:1527 ||| NN
perception  ||| S:1527 E:1538 ||| NN
were  ||| S:1538 E:1543 ||| VBD
more  ||| S:1543 E:1548 ||| RBR
likely  ||| S:1548 E:1555 ||| JJ
to  ||| S:1555 E:1558 ||| TO
be  ||| S:1558 E:1561 ||| VB
concerned  ||| S:1561 E:1571 ||| VBN
about  ||| S:1571 E:1577 ||| IN
breast  ||| S:1577 E:1584 ||| JJ
cancer  ||| S:1584 E:1591 ||| NN
( ||| S:1591 E:1592 ||| -LRB-
OR=5.1 ||| S:1592 E:1598 ||| NNP
;  ||| S:1598 E:1600 ||| :
95 ||| S:1600 E:1602 ||| CD
% ||| S:1602 E:1603 ||| NN
CI=2.7-9.6 ||| S:1603 E:1613 ||| CD
) ||| S:1613 E:1614 ||| -RRB-
.  ||| S:1614 E:1616 ||| .
Many  ||| S:1616 E:1621 ||| JJ
women  ||| S:1621 E:1627 ||| NNS
did  ||| S:1627 E:1631 ||| VBD
not  ||| S:1631 E:1635 ||| RB
accurately  ||| S:1635 E:1646 ||| RB
perceive  ||| S:1646 E:1655 ||| VB
their  ||| S:1655 E:1661 ||| PRP$
risk  ||| S:1661 E:1666 ||| NN
for  ||| S:1666 E:1670 ||| IN
breast  ||| S:1670 E:1677 ||| JJ
cancer ||| S:1677 E:1683 ||| NN
.  ||| S:1683 E:1685 ||| .
Women  ||| S:1685 E:1691 ||| NNS
with  ||| S:1691 E:1696 ||| IN
accurate  ||| S:1696 E:1705 ||| JJ
risk  ||| S:1705 E:1710 ||| NN
perception  ||| S:1710 E:1721 ||| NN
had  ||| S:1721 E:1725 ||| VBD
an  ||| S:1725 E:1728 ||| DT
appropriate  ||| S:1728 E:1740 ||| JJ
level  ||| S:1740 E:1746 ||| NN
of  ||| S:1746 E:1749 ||| IN
concern  ||| S:1749 E:1757 ||| NN
about  ||| S:1757 E:1763 ||| IN
breast  ||| S:1763 E:1770 ||| JJ
cancer ||| S:1770 E:1776 ||| NN
.  ||| S:1776 E:1778 ||| .
Improved  ||| S:1778 E:1787 ||| JJ
methods  ||| S:1787 E:1795 ||| NNS
of  ||| S:1795 E:1798 ||| IN
assessing  ||| S:1798 E:1808 ||| VBG
and  ||| S:1808 E:1812 ||| CC
informing  ||| S:1812 E:1822 ||| VBG
women  ||| S:1822 E:1828 ||| NNS
of  ||| S:1828 E:1831 ||| IN
their  ||| S:1831 E:1837 ||| PRP$
breast  ||| S:1837 E:1844 ||| NN
cancer  ||| S:1844 E:1851 ||| NN
risk  ||| S:1851 E:1856 ||| NN
could  ||| S:1856 E:1862 ||| MD
motivate  ||| S:1862 E:1871 ||| VB
high  ||| S:1871 E:1876 ||| JJ
risk  ||| S:1876 E:1881 ||| NN
women  ||| S:1881 E:1887 ||| NNS
to  ||| S:1887 E:1890 ||| TO
apply  ||| S:1890 E:1896 ||| VB
appropriate  ||| S:1896 E:1908 ||| JJ
prevention  ||| S:1908 E:1919 ||| NN
strategies  ||| S:1919 E:1930 ||| NNS
and  ||| S:1930 E:1934 ||| CC
allay  ||| S:1934 E:1940 ||| VB
unnecessary  ||| S:1940 E:1952 ||| JJ
concern  ||| S:1952 E:1960 ||| NN
among  ||| S:1960 E:1966 ||| IN
average  ||| S:1966 E:1974 ||| JJ
risk  ||| S:1974 E:1979 ||| NN
women ||| S:1979 E:1984 ||| NNS
.  ||| S:1984 E:1986 ||| .
